
OS Therapies Inc — Investor Relations & Filings
OS Therapies Inc. is a clinical-stage cancer immunotherapy company focused on developing treatments for cancers that express the HER2 protein. The company's approach is to activate the patient's immune system to target and destroy tumor cells. Its lead candidate, OST-HER2, is a therapeutic vaccine initially being developed for osteosarcoma, a type of bone cancer with a significant unmet medical need. The company plans to expand the development of its technology to other HER2-positive solid tumors, including breast, colorectal, esophageal, lung, and ovarian cancers. The pipeline also includes proprietary technologies like OST-tADC Tunable Drug Conjugates.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-18 | English | |
| 424B5 - OS Therapies Inc (0001795091) (Filer) | 2026-04-02 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46383305 | QUARTERLY REPORT | 2026-05-18 | English | ||
| 33196663 | 424B5 - OS Therapies Inc (0001795091) (Filer) | 2026-04-02 | English | ||
| 32898412 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898413 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898414 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898415 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898416 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898417 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898418 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 31749726 | 4 Filing | 2026-02-13 | English | ||
| 31749645 | 8-K Filing | 2026-02-13 | English | ||
| 13219850 | Regulatory Filings 2026 | 2026-01-20 | English | ||
| 13219851 | CURRENT REPORT | 2026-01-12 | English | ||
|
2025
2 filings
| |||||
| 13219852 | Director's Dealing 2025 | 2025-12-20 | English | ||
| 13219853 | Director's Dealing 2025 | 2025-12-20 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aptose Biosciences Inc.
Clinical-stage company developing targeted precision medici…
|
APS | CA | Professional, scientific and te… |
|
APURES CO., LTD.
Biotech firm providing MICROPIG models, bio-resources, and …
|
149300 | KR | Professional, scientific and te… |
|
Aran Research & Development (1982) Ltd.
A product design and development firm providing services fr…
|
ARAN | IL | Professional, scientific and te… |
|
Arch Biopartners Inc.
Developing novel drugs for acute kidney injury (AKI) and ch…
|
ARCH | CA | Professional, scientific and te… |
|
ARCHER MATERIALS LIMITED
Develops semiconductor devices for quantum computing and me…
|
AXE | AU | Professional, scientific and te… |
|
ARGENICA THERAPEUTICS LIMITED
Clinical-stage developer of neuroprotective drugs for acute…
|
AGN | AU | Professional, scientific and te… |
|
ARIUS Research Inc.
Discovery and development of targeted antibody therapeutics…
|
ARI | CA | Professional, scientific and te… |
|
AROVELLA THERAPEUTICS LIMITED
Develops off-the-shelf iNKT cell therapies for blood cancer…
|
ALA | AU | Professional, scientific and te… |
|
Artiva Biotherapeutics, Inc.
Develops allogeneic, off-the-shelf NK cell therapies for ca…
|
ARTV | US | Professional, scientific and te… |
|
ARVINAS, INC.
Clinical-stage biopharma developing therapeutics based on t…
|
ARVN | US | Professional, scientific and te… |
OS Therapies Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34454/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34454 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34454 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34454 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34454}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for OS Therapies Inc (id: 34454)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.